Momelotinib Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Video

Dr Aaron Gerds discusses the long term safety data of momelotinib, a JAK1/JAK2 inhibitor, in patients with myelofibrosis.

Related Videos
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Related Content